PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2025

Description

PD-1 and PDL1 inhibitors, also known as immune checkpoint inhibitors, belong to the class of immunotherapy drugs employed in cancer treatment. They function by directing the immune system to identify and combat cancer cells effectively. Widely applied across various cancer conditions, these therapies serve as vital components in cancer treatment protocols.

Key products within the PD-1 and PDL1 inhibitor category include nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. Nivolumab, specifically a PD-1 inhibitor, operates by impeding the PD-1 receptor present on T cells, thereby thwarting cancer cells' ability to evade immune system attacks. These inhibitors find application in treating a spectrum of cancers such as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, among others.

These immunotherapy drugs are available through various channels including hospital pharmacies, retail pharmacies, and online platforms. They are predominantly utilized within hospital settings, specialty clinics, as well as academic and research institutions, constituting integral elements in comprehensive cancer care and research endeavors.

The PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market size has grown rapidly in recent years. It will grow from$45.8 billion in 2024 to $53.15 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to immunotherapy advancements, increased clinical success and approvals, increased cancer incidence, a shift in cancer treatment paradigm, collaborations, and research investments

The PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $91.97 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to expanding indications, biomarker research and personalized medicine, clinical trials and research collaborations, and global healthcare infrastructure development. Major trends in the forecast period include a focus on patient access and affordability, global clinical trial collaborations, immunotherapy combinations, patient-centric approaches, regulatory updates, and approvals.

The projected growth in the PD-1 and PD-L1 Inhibitors, also known as Immune Checkpoint Inhibitors, market is heavily influenced by the escalating prevalence of cancer cases. Cancer, characterized by uncontrolled cell growth and dissemination, has seen a noticeable increase in cases over recent years. PD-1 and PD-L1 inhibitors play a crucial role in treating cancer by leveraging the body's immune system to combat cancer cells effectively. For example, as per the European Union Science Hub's findings in October 2023, the preceding two years witnessed a 2.3% rise in new cancer cases, reaching 2.74 million, alongside a 2.4% increase in cancer-related deaths. This surge in cancer incidence significantly contributes to the growth anticipated in the PD-1 and PD-L1 Inhibitors market.

The anticipated growth in the PD-1 and PD-L1 Inhibitors market is closely tied to the increasing emphasis on personalized medicine. This advanced healthcare approach considers unique patient factors such as genetics, behaviors, and environmental influences in treatment strategies. In the context of PD-1 and PD-L1 inhibitors, personalized medicine involves tailoring cancer therapies to optimize efficacy and minimize potential adverse effects based on individual patient characteristics and biomarker expressions. Notably, the Personalized Medicine Coalition's data from February 2023 revealed that personalized medications accounted for 34% of newly approved pharmaceuticals by the US FDA in 2022, showcasing a sustained upward trend. This growing focus on personalized medicine significantly drives the PD-1 and PD-L1 Inhibitors market forward.

Product innovation has emerged as a pivotal trend shaping the landscape of PD-1 and PD-L1 Inhibitors, or immune checkpoint inhibitors. Leading market players are strategically channeling efforts towards developing innovative products to bolster their market presence. For instance, Bristol-Myers Squibb's successful FDA approval for Opdualag in March 2022 marked a breakthrough-a fixed-dose combination of nivolumab (Opdivo) and relatlimab, the latter being a LAG-3 inhibitor. Opdualag, the first LAG-3 inhibitor approved by the US FDA for treating metastatic melanoma, aims to augment immune responses against cancer cells, showcasing a substantial leap in product innovation within this sector.

Strategic investments play a crucial role in shaping the landscape of the PD-1 and PD-L1 Inhibitors market. Major companies operating in this domain are leveraging strategic initiatives to fortify their positions. For instance, Regeneron Pharmaceuticals, Inc.'s investment in June 2022 involved acquiring Sanofi's share in the Regeneron and Sanofi partnership concerning Libtayo (cemiplimab). This strategic move conferred Regeneron exclusive rights to develop, market, and manufacture Libtayo globally. Valued at $900 million, plus royalties and potential future milestone payments, this investment aimed to bolster Regeneron's foothold in the market. Libtayo, a first-in-class PD-1 inhibitor developed using Regeneron's VelocImmune technology, gained approval from the FDA and numerous global regulatory bodies, solidifying its position as a standard treatment for certain advanced non-small cell lung cancer, cutaneous squamous cell carcinoma, and basal cell carcinoma cases.

In June 2023, Coherus BioSciences, a leading U.S.-based biopharmaceutical company specializing in cancer therapeutics, acquired Surface Oncology for $65 million. This acquisition enhances Coherus' portfolio by incorporating innovative immuno-oncology therapies, including Surface's IL-27-targeted antibody (SRF388) and CCR8-targeted antibody (SRF114). With this acquisition, Coherus can now provide a diverse range of clinical-stage immunotherapies designed to boost the immune response against tumors, including applications for lung and liver cancer. Surface Oncology is a U.S.-based firm engaged in developing PD-1 and PD-L1 inhibitors, which are essential elements of immune checkpoint therapy for cancer treatment.

Major companies operating in the PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy's Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.

North America was the largest region in the PD-1 and PDL1 inhibitors market in 2024. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market consists of sales of various inhibitors such as cemiplimab, sintilimab, and camrelizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab
2) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online pharmacies
3) By Application: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin Lymphoma; Colorectal Cancer; Other Applications
4) By End-Users : Hospitals; Specialty Clinics; Academic and Research Institutions
Subsegments:
1) By Nivolumab: Monotherapy; Combination Therapy
2) By Pembrolizumab: Monotherapy; Combination Therapy
3) By Atezolizumab: Monotherapy; Combination Therapy
4) By Avelumab: Monotherapy; Combination Therapy
5) By Durvalumab: Monotherapy; Combination Therapy
Companies Mentioned: Bristol-Myers Squibb Company; Merck and Company; F. Hoffmann-La Roche AG; Sanofi S.A.; Amgen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24395

1. Executive Summary

2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Characteristics

3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Trends And Strategies

4. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Growth Analysis And Strategic Analysis Framework

5.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Growth Rate Analysis
5.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Total Addressable Market (TAM)

6. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Segmentation

6.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nivolumab
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab
6.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital pharmacies
Retail pharmacies
Online pharmacies
6.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lung Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma
Colorectal Cancer
Other Applications
6.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Academic and Research Institutions
6.5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.6. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Pembrolizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.7. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Atezolizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.8. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Avelumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.9. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Sub-Segmentation Of Durvalumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy

7. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Regional And Country Analysis

7.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

8.1. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

9.1. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
9.2. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

10.1. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

11.1. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
11.2. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

12.1. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

13.1. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

14.1. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
14.2. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

15.1. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
15.2. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

16.1. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

17.1. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

18.1. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

19.1. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

20.1. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

21.1. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
21.2. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

22.1. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

23.1. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
23.2. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

24.1. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
24.2. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

25.1. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
25.2. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

26.1. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
26.2. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

27.1. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

28.1. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
28.2. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

29.1. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
29.2. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

30.1. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape
30.2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Company Profiles
- 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Other Major And Innovative Companies

31.1. Gilead Sciences Inc.
31.2. AstraZeneca plc
31.3. Novartis AG
31.4. Pfizer Inc.
31.5. GlaxoSmithKline Plc
31.6. Regeneron Pharmaceuticals Inc.
31.7. BeiGene Ltd
31.8. Shanghai Jhunsi Biosciences Ltd.
31.9. Akeso Inc.
31.10. Alphamab Oncology
31.11. Eli Lilly and Company
31.12. Boehringer Ingelheim
31.13. Xencor Inc.
31.14. Taiga Biotechnologies Inc.
31.15. Jiangsu Alphamab Biopharmaceuticals Co. Ltd

32. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

34. Recent Developments In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

35. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market High Potential Countries, Segments and Strategies

35.1 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2029 - Countries Offering Most New Opportunities
35.2 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2029 - Segments Offering Most New Opportunities
35.3 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer